ARVO

The programme includes thousands of poster and paper presentations by up-and-coming vision scientists and world leaders in their respective subspecialties.

The host city of New Orleans, Louisiana, US, is replete with old world charm and ambiance and can satisfy any sightseeing, gastronomic and musical appetites.

The 2023 Association for Research in Vision and Ophthalmology (ARVO) annual meeting promises to provide numerous opportunities to meet up with old friends and colleagues and forge relationships with new ones as well as enhance future research and practice endeavors.

The Association for Research in Vision and Ophthalmology (ARVO) 2023 annual meeting is convening in New Orleans from April 23 to 27 at the Ernest N. Morial Convention Center. The theme of the Annual Meeting speaks both to the mechanistic diversity in ocular disease in addition to the diversity of vision scientists who are from multiple backgrounds and perspectives.

Richard Rosen, MD, shares insights on how imaging can capture hyalocytes and their movement without the use of dyes.

Dr Sally Tucker of Ora Europe walks through the clinical trial pathway, describing how Ora addresses complexities to make the path as efficient as possible.

The study assesses retinal blood biomarkers using a new prototype OCT, aiming to measure retinal biomarkers such as blood flow volume, average velocity, and vessel diameter with a new prototype.

Jeff Cleland, PhD, CEO of Ashvattha, discusses safety data for an at-home subcutaneous anti-VEGF injection option in development for the treatment of wet AMD and DMO.

Takeaway: there doesn't seem to be a specific dry eye phenotype that does better or worse.

The OpRegen trial is a cell therapy trial, looking to explore potential safety and efficacy for patients with advanced dry age-related macular degeneration (AMD).

The study assesses retinal blood biomarkers using a new prototype OCT, aiming to measure retinal biomarkers such as blood flow volume, average velocity and vessel diameter with a new prototype.

The study found that if certain forms of nystagmus that are seen in patients, then there is a higher chance of poor binocular visual function, as well as higher interocular suppression.

Presented at ARVO 2022, research from Mass Eye and Ear hopes to open a new avenue for therapies that are for helping treat patients that develop primary open angle glaucoma.

Dr Carlos Quezada Ruiz, senior medical director at Genentech, discusses “Predicting optimal treatment regimen for patients with neovascular age-related macular degeneration using machine learning.”

The study assess retinal blood biomarkers using a new prototype OCT, aiming to measure retinal biomarkers such as blood flow volume, average velocity, and vessel diameter with a new prototype.

The study evaluates three separate cases, each of which experienced irreversible changes in their corneal structure caused by challenges in getting timely treatment due to various reasons, including insurance, lost to follow up, and the COVID-19 pandemic.

Carlos Quezada Ruiz, MD, senior medical director at Genentech, discusses “Predicting optimal treatment regimen for patients with neovascular age-related macular degeneration using machine learning.”

Presented at ARVO 2022, research from Mass Eye and Ear hopes to open a new avenue for therapies that are for helping treat patients that develop primary open angle glaucoma.

Carlos Quezada Ruiz, MD, senior medical director at Genentech, discusses “Predicting optimal treatment regimen for patients with neovascular age-related macular degeneration using machine learning.”

Jeff Cleland, PhD, CEO of Ashvattha, discusses safety data for an at-home subcutaneous injection option being developed for wet AMD and DME. The anti-VEGF candidate will enter a Phase 2 study later this year.

Presented at ARVO 2022, research from Mass Eye and Ear hopes to open a new avenue for therapies that are for helping treat patients that develop primary open angle glaucoma.

The Phase 3 integrated PEACHTREE and AZALEA study data revealed strong safety and efficacy for triamcinolone acetonide via suprachoirodal injection.

The study found that if certain forms of nystagmus that are seen in patients, then there is a higher chance of poor binocular visual function, as well as higher interocular suppression.

Ora's Caitlin Black, senior director and therapeutic area head of medical devices, talks about the next generation of ophthalmic device therapies and diagnostics, clinical trial updates and new innovations that are most exciting for presbyopia treatment.

The OpRegen trial is a cell therapy trial, looking to explore potential safety and efficacy for patients with advanced dry age-related macular degeneration (AMD).

The study found that if certain forms of nystagmus that are seen in patients, then there is a higher chance of poor binocular visual function, as well as higher interocular suppression.

The study evaluates three separate cases, each which experiences irreversible changes in their corneal structure caused by challenges in getting timely treatment due to various reasons, including insurance, lost to follow up, and the coronavirus pandemic.

At ARVO 2022 in Denver, Colorado, Timothy Blenkinsop, MD, presented “3D Eye Organoids with Distinct Cornea.” His presentation outlined how these organoids have developed sophisticated cornea structures.

The Phase 3 integrated PEACHTREE and AZALEA study data revealed strong safety and efficacy for triamcinolone acetonide via suprachoirodal injection.